Biotech Values

[biomaven0]

Well Natrecor, which was inpatient only, did pretty well until safety issues emerged down the line. (They did explore outpatient use but I don't think they got very far).

The key issue here is need is very great and, as you pointed out, all alternatives that make the patient feel better also increase mortality. So in some sense the bar is quite low, although the FDA will be tough after their Natrecor experience.

I've never followed the company myself - just pointing out that there is a very large market out there if you can show even moderate efficacy and no adverse impact on mortality.

(Natrecor if I recall correctly was approved based on short-term improved EF and subjective reports of how patients felt).

Peter